Pfizer bets on Rx-to-OTC Nexium switch

Share this article:
Pfizer bets on Rx-to-OTC Nexium switch
Pfizer bets on Rx-to-OTC Nexium switch
Pfizer is making a multimillion-dollar bet that the over-the-counter (OTC) reflux market is worth a gander. The company said Tuesday that it's scooping up worldwide marketing rights to the non-prescription version of AstraZeneca's blockbuster proton-pump inhibitor, which AZ would start supplying to Pfizer's consumer care unit upon the OTC med's possible approval, for $250 million up front. The down payment could be a lead-in for additional milestone and royalty payments as the relationship continues.

The deal is a positive one for AstraZeneca, which has been slogging through a leadership change, massive layoffs and, most recently, a failed sepsis drug. A company statement indicated that Tuesday's Nexium deal is also an entry point for further collaboration: AstraZeneca has given Pfizer first refusal rights for the OTC version of the hay fever spray Rhinocort Aqua.

Sales of Nexium's prescription GERD medication, launched in the US in 2001, have been on the decline. Worldwide sales have fallen to $949 million during the first half of the year, a 13% drop compared to the same period last year. Annual sales faltered in 2011, with Nexium sales declining to $4.4 billion, 12% less than that drug's sales in 2010. The drug is slated to lose US patent exclusivity in 2014.

“This agreement will help AstraZeneca realize the substantial, long-term value of this brand and potentially other brands in our portfolio,” Tony Zook, VP of global commercial optimization for AZ, said in a joint company statement. He added that Pfizer Consumer Healthcare is the "optimal partner to commercialise OTC Nexium globally."

An OTC version of the drug has not yet been approved, and AstraZeneca will continue to manufacture the prescription version of the medication. An application for an OTC version of the drug went before European regulators in June. The companies said the FDA should expect to receive an OTC application in the first half of 2013. Pfizer said in the statement it expects to launch OTC Nexium in the US by 2014.

Pfizer's not the only drugmaker looking to make money off of Rx-to-OTC switch opportunities. Sanofi is doing the same with allergy drug Allegra, an OTC version of which secured FDA approval last year, while Merck has been unsuccessful in several attempts to get OTC approval for its statin Mevacor. Pfizer itself was said to be weighing an attempt at an OTC switch for Lipitor last year.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...